Citations

Clear

27 citation(s) found for "Silverberg, M".

Development of an index to define overall disease severity in IBD
Whitman, Cynthia B. , Spiegel, Brennan , Feagan, Brian G. , Loftus, Edward V. , D’Haens, Geert , Bernstein, Çharles N. , Gearry, Richard B. , Mantzaris, Gerassimos J. , Sartor, Balfour R., Silverberg, Mark S. , Riddell, Robert H. , O’Morain, Colm, Lakatos, Péter L. , Halfvarson, Jonas , Reinisch, Walter, Rogler, Gerhard , Kruis, Wolfgang , Tysk, Curt , Danese, Silvio , Sandborn, William J. , Gasché, Christoph , Pallone, Francesco, Travis, Simon , Peyrin‐Biroulet, Laurent , Siegel, Corey A , Sands, Bruce E , Panaccione, Remo , Bernstein, Charles Noah , Ng, Siew C. , Κoutroubakis, Ioannis E. , McGovern, Dermot , Halfvarson, Jonas , Schreiber, Stefan , Griffiths, Anne Marie , Moum, Bjørn Allan , Panés, Julián , Colombel, Jean‐Frédéric , Hanauer, Stephen B. , Loftus, Edward V , Danese, Silvio , Peyrin-Biroulet, Laurent , Spiegel, Brennan , Lakatos, Peter L

Mayo Clinic

Gut | October 25, 2016 | Volume: 67 | Issue: 2 | Pages: 244-254

10.1136/gutjnl-2016-312648 | PMID 27780886 Get It

Background and aim Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC. Methods Using a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD. Eighteen IOIBD members then completed a statistical exercise (conjoint analysis) to create a relative ranking of these attributes. Adjusted utilities were developed by creating proportions for each level within an attribute. Results For CD, 15.8% of overall disease severity was attributed to the presence of mucosal lesions, 10.9% to history of a fistula, 9.7% to history of abscess and 7.4% to history of intestinal resection. For UC, 18.1% of overall disease severity was attributed to mucosal lesions, followed by 14.0% for impact on daily activities, 11.2% C reactive protein and 10.1% for prior experience with biologics. Overall disease severity indices were created on a 100-point scale by applying each attribute's average importance to the adjusted utilities. Conclusions Based on specialist opinion, overall CD severity was associated more with intestinal damage, in contrast to overall UC disease severity, which was more dependent on symptoms and impact on daily life. Once validated, disease severity indices may provide a useful tool for consistent assessment of overall disease severity in patients with IBD.
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Silverberg, Mark S. , Satsangi, Jack, Ahmad, Tariq , Arnott, Ian , Bernstein, Çharles N. , Caprilli, R., Colombel, Jean–Frédéric, Gasché, Christoph , Geboes, Karel, Jewell, Derek P., Karban, Amir, Peña, A. S. , Riddell, Robert H. , Sachar, David B., Steinhart, A. Hillary , Targan, Stephan R. , Vermeire, Séverine , Warren, Bryan F., Bernstein, Charles Noah , Brant, Steven R , Loftus, Edward V. , Schreiber, Stefan , Vermeire, Séverine

Mayo Clinic

Canadian Journal of Gastroenterology | May 17, 2016 | Volume: 19 | Issue: suppl a | Pages: 5A-36A

10.1155/2005/269076 | PMID 16151544 Get It

The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn’s disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology
Darragh, Teresa M. , Colgan, Terence J. , Cox, J. Thomas, Heller, Debra S. , Henry, Michael , Luff, Ronald D., McCalmont, Timothy H. , Nayar, Ritu , Stoler, Mark H. , Wilkinson, Edward J., Zaino, Richard J., Wilbur, David C. , Luff, Ronald D., Wilkinson, Edward J., Wilkinson, Edward J., O’Connor, Dennis M., Reynolds, R. Kevin, Selim, M. Angélica , Scurry, James , Chelmow, David , Howell, Lydia, Ronnett, Brigitte M., Waxman, Alan G., Haefner, Hope K. , Leslie, Kieron , Lytwyn, Alice, Winkler, Barbara , Colgan, Terence J., Downs, Levi S., Laucirica, Rodolfo, Allbritton, Jill, Ioffe, Olga B. , Joste, Nancy E., Berry, J. Michael, Lin, Oscar , Welton, Mark L., Otis, Christopher N. , Stoler, Mark H. , Bentz, Joel S., Quade, Bradley J. , Schwartz, Mary R. , Luff, Ronald D., Castle, Philip E. , García, Francisco , Moriarty, Ann , Niedt, Greg , Carter, Alicia , Neal, Margaret B., Reddy, Vijaya , Robboy, Stanley J. , Spires, Susan E., Luff, Ronald D., Palefsky, Joel Michael , Wilkinson, Edward J., Wilkinson, Edward J., Shea, Christopher Michael , Staats, Paul N. , Roberts, Jennifer Margaret , Colgan, Terence J., Kong, Christina S. , Luff, Ronald D., Duggan, Máire A. , Goodman, Marc T. , Saraiya, Mona , Silverberg, Steven M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 28, 2012 | Volume: 136 | Issue: 10 | Pages: 1266-1297

10.5858/arpa.lgt200570 | PMID 22742517 Get It

Abstract The terminology for human papillomavirus (HPV)–associated squamous lesions of the lower anogenital tract has a long history marked by disparate diagnostic terms derived from multiple specialties. It often does not reflect current knowledge of HPV biology and pathogenesis. A consensus process was convened to recommend terminology unified across lower anogenital sites. The goal was to create a histopathologic nomenclature system that reflects current knowledge of HPV biology, optimally uses available biomarkers, and facilitates clear communication across different medical specialties. The Lower Anogenital Squamous Terminology (LAST) Project was cosponsored by the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology and included 5 working groups; 3 work groups performed comprehensive literature reviews and developed draft recommendations. Another work group provided the historical background and the fifth will continue to foster implementation of the LAST recommendations. After an open comment period, the draft recommendations were presented at a consensus conference attended by LAST work group members, advisors, and representatives from 35 stakeholder organizations including professional societies and government agencies. Recommendations were finalized and voted on at the consensus meeting. The final, approved recommendations standardize biologically relevant histopathologic terminology for HPV-associated squamous intraepithelial lesions and superficially invasive squamous carcinomas across all lower anogenital tract sites and detail the appropriate use of specific biomarkers to clarify histologic interpretations and enhance diagnostic accuracy. A plan for disseminating and monitoring recommendation implementation in the practicing community was also developed. The implemented recommendations will facilitate communication between pathologists and their clinical colleagues and improve accuracy of histologic diagnosis with the ultimate goal of providing optimal patient care.
Assessment of cognition in early dementia
Silverberg, Nina, Ryan, Laurie, Petersen, Ronald C. , Posner, Holly, Hilsabeck, Robin C. , Rizzo, Albert, Ott, Brian R. , Albert, Marilyn S. , Wagster, Molly V., Schinka, John A., Cullum, C. Munro , Farias, Sarah Tomaszewski , Balota, David A., Budson, Andrew E. , Strutt, Adriana M. , Gollan, Tamar H. , Babcock, Debra, Kramer, Joel H. , Carrillo, María C. , Sperling, Reisa Anne , Snyder, Peter J. , Gallagher, Michela , Raber, Jacob , Possin, Katherine L. , King, Jonathan W. , Kaye, Jeffrey , Rao, Stephen M. , Loewenstein, David , Brandt, Jason , Manly, Jennifer J. , Barnes, Lisa L. , Ganguli, Mary , Litvan, Irene , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 3 | Pages: No page available

10.1016/j.jalz.2011.05.001 | PMID 23559893 Get It

Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease (AD) are required to enable diagnosis of the disease before substantial neurodegeneration has taken place and to allow for detection of subtle changes in the early stages of progression of the disease. The National Institute on Aging and the Alzheimer's Association convened a meeting to discuss state‐of‐the art methods for cognitive assessment, including computerized batteries, as well as new approaches in the pipeline. Speakers described research using novel tests of object recognition, spatial navigation, attentional control, semantic memory, semantic interference, prospective memory, false memory, and executive function as among the tools that could provide earlier identification of individuals with AD. In addition to early detection, there is a need for assessments that reflect real‐world situations so as to better assess functional disability. It is especially important to develop assessment tools that are useful in ethnically, culturally, and linguistically diverse populations as well as in individuals with neurodegenerative disease other than AD.
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, Alex E., Esh, Chera L., Kokjohn, Tyler A., Castaño, Eduardo M., Vickle, Gregory D. Van, Kalback, Walter M., Patton, Rebekah , Luehrs, Dean C., Daugs, Ian D., Kuo, Yu‐Min , Emmerling, Mark R., Soares, Holly , Quinn, Joseph F. , Kaye, Jeffrey , Connor, Donald J., Silverberg, Nina, Seward, James D., Beach, Thomas G. , Adler, Charles H. , Sabbagh, Marwan Noel , Quinn, Joseph F

Mayo Clinic

Alzheimer's & Dementia | December 31, 2008 | Volume: 5 | Issue: 1 | Pages: 18-29

10.1016/j.jalz.2008.10.004 | PMID 19118806 Get It

BackgroundWe evaluated the amounts of amyloid beta (Aβ)) peptides in the central nervous system (CNS) and in reservoirs outside the CNS and their potential impact on Aβ plasma levels and Alzheimer's disease (AD) pathology.MethodsAmyloid β levels were measured in (1) the plasma of AD and nondemented (ND) controls in a longitudinal study, (2) the plasma of a cohort of AD patients receiving a cholinesterase inhibitor, and (3) the skeletal muscle, liver, aorta, platelets, leptomeningeal arteries, and in gray and white matter of AD and ND control subjects.ResultsPlasma Aβ levels fluctuated over time and among individuals, suggesting continuous contributions from brain and peripheral tissues and associations with reactive circulating proteins. Arteries with atherosclerosis had larger amounts of Aβ40 than disease‐free vessels. Inactivated platelets contained more Aβ peptides than activated ones. Substantially more Aβ was present in liver samples from ND patients. Overall, AD brain and skeletal muscle contained increased levels of Aβ.ConclusionsEfforts to use plasma levels of Aβ peptides as AD biomarkers or disease‐staging scales have failed. Peripheral tissues might contribute to both the circulating amyloid pool and AD pathology within the brain and its vasculature. The wide spread of plasma Aβ values is also due in part to the ability of Aβ to bind to a variety of plasma and membrane proteins. Sources outside the CNS must be accounted for because pharmacologic interventions to reduce cerebral amyloid are assessed by monitoring Aβ plasma levels. Furthermore, the long‐range impact of Aβ immunotherapy on peripheral Aβ sources should also be considered.
Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma
Silverberg, Shonni J. , Rubin, Mishaela R. , Faiman, Charles, Peacock, Munro , Shoback, Dolores , Smallridge, Robert C., Schwanauer, L. E., Olson, Kurt, Klassen, Preston, Bilezikian, John P.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 31, 2007 | Volume: 92 | Issue: 10 | Pages: 3803-3808

10.1210/jc.2007-0585 | PMID 17666472 Get It